[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"app-context":3,"blog-heres-why-regeneron-stock-could-deliver-60-upside-returns-FR":222},{"languages":4,"categories":41,"products":125,"competitors":149},[5,9,13,17,21,25,29,33,37],{"name":6,"code":7,"id":8},"English","EN","TGFuZ3VhZ2U6ZW4=",{"name":10,"code":11,"id":12},"Español","ES","TGFuZ3VhZ2U6ZXM=",{"name":14,"code":15,"id":16},"Português","PT","TGFuZ3VhZ2U6cHQ=",{"name":18,"code":19,"id":20},"日本語","JA","TGFuZ3VhZ2U6amE=",{"name":22,"code":23,"id":24},"한국어","KO","TGFuZ3VhZ2U6a28=",{"name":26,"code":27,"id":28},"Deutsch","DE","TGFuZ3VhZ2U6ZGU=",{"name":30,"code":31,"id":32},"Italiano","IT","TGFuZ3VhZ2U6aXQ=",{"name":34,"code":35,"id":36},"Français","FR","TGFuZ3VhZ2U6ZnI=",{"name":38,"code":39,"id":40},"中文 (中国)","ZH","TGFuZ3VhZ2U6emg=",[42,73,104],{"icon":43,"slug":44,"title":45,"description":46,"featuredLinks":47},"mingcute:stock-line","stock-market-basics","Stock Market Basics","\u003Cp>Beginners' guides and practical tips for understanding stock market investing.\u003C\u002Fp>\n",[48,53,58,63,68],{"url":49,"title":50,"description":51,"ogImage":52},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-makes-stocks-go-up-and-down","What Makes Stocks Go Up and Down | TIKR.com","Understanding what makes stock prices go up and down can help investors better navigate investing. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-makes-stocks-go-up-and-down-banner\u002FWhat-makes-stocks-go-up-and-down-banner.jpg?_i=AA",{"url":54,"title":55,"description":56,"ogImage":57},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fdividend-yield-meaning-formula-example","Dividend Yield: Meaning, Formula, Example | Tikr.com Blog | TIKR.com","The dividend yield is a key metric for investors looking to gauge the income potential of their investments. It measures how much a company pays out in","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FDividend-yield\u002FDividend-yield.png?_i=AA",{"url":59,"title":60,"description":61,"ogImage":62},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fmarket-capitalization-definition-formula-and-why-it-matters","Market Capitalization: Definition, Formula, and Why It Matters | TIKR.com","Long-term investors often look at various valuation metrics when deciding whether to invest in a particular company. One helpful metric to evaluate is","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters.png?_i=AA",{"url":64,"title":65,"description":66,"ogImage":67},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fearnings-per-share-definition-formula-and-why-eps-matters","Earnings Per Share: Definition, Formula, and Why EPS Matters | TIKR.com","Earnings Per Share (EPS) represents the portion of a company's net earnings allocated to each share. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEPS-Defiinition-formula-and-why-EPS-matters-1\u002FEPS-Defiinition-formula-and-why-EPS-matters-1.png?_i=AA",{"url":69,"title":70,"description":71,"ogImage":72},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-stock-price-target","What Is a Stock Price Target? | TIKR.com","A price target is a stock's estimated future price. It can help investors quickly find undervalued stocks. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-Stock-Price-Target-2\u002FWhat-is-a-Stock-Price-Target-2.png?_i=AA",{"icon":74,"slug":75,"title":76,"description":77,"featuredLinks":78},"material-symbols:analytics-outline","fundamental-analysis","Fundamental Analysis","\u003Cp>In-depth resources and financial metrics to help you evaluate companies like a pro.\u003C\u002Fp>\n",[79,84,89,94,99],{"url":80,"title":81,"description":82,"ogImage":83},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fshare-repurchase-why-do-companies-buy-back-their-stock","Share Repurchase: Why Do Companies Buy Back Their Stock? | TIKR.com","Share repurchases, or share buybacks, have gained popularity in the last two decades. According to a report from Goldman Sachs, stock buybacks initiated","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e.png?_i=AA",{"url":85,"title":86,"description":87,"ogImage":88},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-invested-capital","What Is a Good Return on Invested Capital? | TIKR.com","Learning about Return on Invested Capital (ROIC) can help investors spot highly profitable stocks that can drive long-term returns. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-Invested-capital\u002FWhat-is-a-good-return-on-Invested-capital.png?_i=AA",{"url":90,"title":91,"description":92,"ogImage":93},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-equity-ratio","What is a Good Return on Equity Ratio | Tikr.com Blog | TIKR.com","Return on Equity (ROE) is a financial ratio that reflects a company's profitability in relation to the equity invested by shareholders. It basically","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-equity-ratio-1\u002FWhat-is-a-good-return-on-equity-ratio-1.jpg?_i=AA",{"url":95,"title":96,"description":97,"ogImage":98},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-p-e-ratio","What Is a Good P\u002FE Ratio? | TIKR.com","Financial analysts and investors look at various metrics before deciding whether a stock is a buy. One of the metrics is the price-to-earnings ratio (P\u002FE","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-PE-ratio-1\u002FWhat-is-a-good-PE-ratio-1.jpg?_i=AA",{"url":100,"title":101,"description":102,"ogImage":103},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Ftop-6-metrics-for-investing-in-reits","Top 6 Metrics for Investing in REITs | TIKR.com","Real estate has been one of the greatest asset classes for wealth creation in history, and investing in Real Estate Investment Trusts (REITs) can allow","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FGroup-10\u002FGroup-10.png?_i=AA",{"icon":105,"slug":106,"title":107,"description":108,"featuredLinks":109},"hugeicons:investigation","investing-lingo","Investing Lingo","\u003Cp>A comprehensive glossary of investing terms and jargon so you can speak the language of the markets confidently.\u003C\u002Fp>\n",[110,115,120],{"url":111,"title":112,"description":113,"ogImage":114},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fenterprise-value-definition-and-calculation","Enterprise Value: Definition and Calculation | Tikr.com Blog | TIKR.com","Enterprise value (EV) is a financial metric that offers a comprehensive snapshot of a company's total value. Unlike market capitalization which solely","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEnterprise-Value-Definition-and-Calculation_37576e40\u002FEnterprise-Value-Definition-and-Calculation_37576e40.png?_i=AA",{"url":116,"title":117,"description":118,"ogImage":119},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Febitda-definition-formula-how-to-use-it","EBITDA: Definition, Formula, How to Use It | TIKR.com","EBITDA stands for earnings before interest, taxes, depreciation and amortization. It's a financial metric commonly used to evaluate a company's financial","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEBITDA-Definition-Formula-How-to-Use-It\u002FEBITDA-Definition-Formula-How-to-Use-It.png?_i=AA",{"url":121,"title":122,"description":123,"ogImage":124},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-the-free-cash-flow-formula-and-why-does-it-matter","What is the Free Cash Flow Formula and Why Does It Matter | TIKR.com","Free cash flow, or FCF, is the cash a company generates after it accounts for outflows required to maintain business operations and support capital","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-the-free-cash-flow-formula\u002FWhat-is-the-free-cash-flow-formula.png?_i=AA",[126,130,134,137,141,145],{"slug":127,"modified":128,"title":129},"valuation-model-builder","2025-07-03T00:18:53","Value Stocks Quickly and Accurately",{"slug":131,"modified":132,"title":133},"stock-portfolio-tracking","2024-12-02T22:21:28","Monitor Your Portfolio",{"slug":75,"modified":135,"title":136},"2025-01-21T22:10:52","Instantly Analyze Companies with In-Depth Metrics",{"slug":138,"modified":139,"title":140},"stock-screener","2024-12-02T22:13:31","Find the Best Stocks to Buy",{"slug":142,"modified":143,"title":144},"investor-stock-portfolio","2025-01-21T22:02:56","Follow Investment Moves of Top Investors",{"slug":146,"modified":147,"title":148},"analyze-stocks","2025-07-23T16:04:24","Analyze Stocks",[150,154,158,162,166,170,174,178,182,186,190,194,198,202,206,210,214,218],{"slug":151,"title":152,"modified":153},"bloomberg","Bloomberg","2025-01-16T14:23:44",{"slug":155,"title":156,"modified":157},"morningstar","Morningstar","2025-01-16T14:25:16",{"slug":159,"title":160,"modified":161},"sentieo","Sentieo","2025-01-16T17:58:27",{"slug":163,"title":164,"modified":165},"googlefinance","Google Finance","2025-01-17T19:39:37",{"slug":167,"title":168,"modified":169},"tradingview","TradingView","2025-01-16T18:17:01",{"slug":171,"title":172,"modified":173},"factset","Factset","2025-01-16T18:20:16",{"slug":175,"title":176,"modified":177},"finviz","Finviz","2025-01-16T18:23:40",{"slug":179,"title":180,"modified":181},"ycharts","YCharts","2025-01-16T18:32:19",{"slug":183,"title":184,"modified":185},"marketbeat","MarketBeat","2025-03-11T00:27:23",{"slug":187,"title":188,"modified":189},"benzinga","Benzinga","2025-03-11T00:31:00",{"slug":191,"title":192,"modified":193},"gurufocus","Gurufocus","2025-03-11T00:31:12",{"slug":195,"title":196,"modified":197},"fast-graphs","FAST Graphs","2025-03-11T00:31:19",{"slug":199,"title":200,"modified":201},"tipranks","TipRanks","2025-03-11T00:31:26",{"slug":203,"title":204,"modified":205},"seeking-alpha","Seeking Alpha","2025-03-11T00:31:45",{"slug":207,"title":208,"modified":209},"thestreet","TheStreet","2025-03-11T00:31:52",{"slug":211,"title":212,"modified":213},"investing-com","Investing.com","2025-03-11T00:32:00",{"slug":215,"title":216,"modified":217},"zacks","Zacks","2025-03-26T15:40:40",{"slug":219,"title":220,"modified":221},"alphasense","AlphaSense","2025-03-11T00:32:15",{"post":223,"seo":259,"relatedPosts":266,"suggestedPosts":344},{"id":224,"title":225,"date":226,"modified":227,"excerpt":228,"content":229,"wordCount":230,"lang":231,"uri":232,"slug":233,"cloudinaryAssetId":234,"featuredImageOriginalUrl":235,"featuredImageMetadata":236,"author":239,"editor":245,"categories":250,"relatedPosts":256,"seo":257},95665,"Voici pourquoi l'action Regeneron pourrait générer des rendements supérieurs de 60 %.","2026-03-04T11:00:00","2026-03-04T03:21:39","\u003Cp>Le Dupixent vient de franchir la barre des 17,8 milliards de dollars de ventes annuelles pour 1,4 million de patients, et avec une neuvième approbation de la FDA maintenant confirmée, les analystes voient 13,6 % de hausse supplémentaire avant que REGN n'atteigne son objectif de prix moyen.\u003C\u002Fp>\n","\n\u003Ch3 class=\"wp-block-heading\" id=\"h-key-stats-for-regeneron-pharmaceuticals-stock\">Statistiques clés de l'action Regeneron Pharmaceuticals\u003C\u002Fh3>\n\n\n\n\u003Cul class=\"wp-block-list\">\n\u003Cli>\u003Cstrong>Performance de la semaine dernière : \u003C\u002Fstrong>+0.2%\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Fourchette de 52 semaines : \u003C\u002Fstrong> 476,5 $ à 821,1\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Cours actuel : \u003C\u002Fstrong> 766,7\u003C\u002Fli>\n\u003C\u002Ful>\n\n\n\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>\u003Cem>La plupart des investisseurs ne savent jamais si une action est réellement sous-évaluée ou surévaluée. Les outils d'évaluation de TIKR, de qualité professionnelle, vous donnent une réponse claire et étayée par des données sur plus de 60 000 actions, et ce gratuitement.\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-what-happened\">\u003Cstrong>Que s'est-il passé ?\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp>L'action Regeneron\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?cid=33715&tid=2642551&ref=tikrblog\">(REGN\u003C\u002Fa>) à 766,66 $ reflète une société qui exécute de multiples victoires réglementaires simultanées tandis que sa franchise DUPIXENT croît à 17,8 milliards de dollars par an pour 1,4 million de patients dans le monde.\u003C\u002Fp>\n\n\n\n\u003Cp>Le 24 février, la FDA a approuvé le Dupixent pour la rhinosinusite fongique allergique chez les patients âgés de 6 ans et plus, ce qui en fait le premier traitement approuvé pour cette pathologie et porte à neuf le nombre d'indications approuvées aux États-Unis.\u003C\u002Fp>\n\n\n\n\u003Cp>Cette neuvième indication vient s'ajouter à une franchise qui génère déjà 4,9 milliards de dollars en un seul trimestre, la part de Regeneron dans les bénéfices de la collaboration avec Sanofi ayant bondi de 42 % d'une année sur l'autre au quatrième trimestre.\u003C\u002Fp>\n\n\n\n\u003Cp>Leonard Schleifer, Président et CEO, a déclaré lors de la conférence téléphonique sur les résultats du quatrième trimestre que \" nous prévoyons au moins 4 approbations de la FDA, dont 3 pour de nouvelles entités moléculaires dans 3 modalités distinctes \", la BLA garetosmab ayant déjà été acceptée par la FDA le 19 février dans le cadre d'une procédure d'examen prioritaire en vue d'une décision au mois d'août.\u003C\u002Fp>\n\n\n\n\u003Cp>Le 27 février, le CHMP de l'EMA a soutenu l'extension du Dupixent aux enfants âgés de 2 à 11 ans pour l'urticaire chronique spontanée, une décision de la FDA est attendue en avril pour la même indication, et le Lynozyfic a atteint une MRD négative chez les neuf patients évaluables ayant récemment reçu un diagnostic de myélome.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>\u003Cem>Découvrez le moment exact où Wall Street revalorise un titre avant que le reste du marché ne le fasse - suivez les changements de notation des analystes en temps réel avec TIKR gratuitement →\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-wall-street-s-take-on-regn-stock\">\u003Cstrong>Le point de vue de Wall Street sur l'action REGN\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp>La neuvième approbation de Dupixent par la FDA le 24 février pour la rhinosinusite fongique allergique élargit directement le bassin de patients adressables qui alimente la franchise de 17,8 milliards de dollars, renforçant les prévisions du consensus pour une croissance des revenus de 9,0% en 2026.\u003C\u002Fp>\n\n\n\n\u003Cp>Les analystes prévoient que les revenus passeront de 14,3 milliards de dollars en 2025 à 15,6 milliards de dollars en 2026, tandis que le BPA normalisé se stabilisera à 44,7 dollars après une baisse de 2,9 %, ce qui indique que l'entreprise a trouvé son seuil de rentabilité avant de ré-accélérer.\u003C\u002Fp>\n\n\n\n\u003Cfigure class=\"wp-block-image size-full\">\u003Cimg width=\"844\" height=\"570\" data-public-id=\"images\u002Fimage-65_95666d7694\u002Fimage-65_95666d7694.png\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_844,h_570,c_scale\u002Ff_webp,q_auto\u002Fv1772593723\u002Fimages\u002Fimage-65_95666d7694\u002Fimage-65_95666d7694.png?_i=AA\" alt=\"regeneron pharmaceuticals stock\" class=\"wp-post-95665 wp-image-95666\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1772593723\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1772593723\u002Fimages\u002Fimage-65_95666d7694\u002Fimage-65_95666d7694.png?_i=AA 844w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_203,c_scale\u002Ff_webp,q_auto\u002Fv1772593723\u002Fimages\u002Fimage-65_95666d7694\u002Fimage-65_95666d7694.png?_i=AA 300w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_768,h_519,c_scale\u002Ff_webp,q_auto\u002Fv1772593723\u002Fimages\u002Fimage-65_95666d7694\u002Fimage-65_95666d7694.png?_i=AA 768w\" sizes=\"auto, (max-width: 844px) 100vw, 844px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">Cible des analystes de la rue pour l'action REGN \u003Cstrong>(\u003C\u002Fstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>TIKR\u003C\u002Fstrong>\u003C\u002Fa>\u003Cstrong>)\u003C\u002Fstrong>\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp>Wall Street compte actuellement 17 acheteurs, 2 surperformants, 8 conservateurs et 1 sous-performant, avec un objectif de prix moyen de 870,7 $, ce qui représente une hausse de 13,6 % par rapport à la clôture du 3 mars de 766,7 $, reflétant la conviction maintenue lors d'un repli prolongé par rapport au sommet de 52 semaines.\u003C\u002Fp>\n\n\n\n\u003Cp>La fourchette d'objectifs des analystes s'étend de 730,0 $ au plus bas à 1 057,0 $ au plus haut, le scénario de hausse dépendant directement de la lecture de la première ligne de mélanome du fianlimab attendue au premier semestre 2026 et de la décision de la FDA concernant le garetosmab en août.\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-what-does-the-valuation-model-say\">\u003Cstrong>Que dit le modèle d'évaluation ?\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cfigure class=\"wp-block-image size-large\">\u003Cimg width=\"1024\" height=\"832\" data-public-id=\"images\u002FREGN_valuation_model-2-1_9566784e2f\u002FREGN_valuation_model-2-1_9566784e2f.webp\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1024,h_832,c_scale\u002Ff_webp,q_auto\u002Fv1772593810\u002Fimages\u002FREGN_valuation_model-2-1_9566784e2f\u002FREGN_valuation_model-2-1_9566784e2f.webp?_i=AA\" alt=\"regeneron pharmaceuticals stock\" class=\"wp-post-95665 wp-image-95667\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1772593810\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1024,h_832,c_scale\u002Ff_webp,q_auto\u002Fv1772593810\u002Fimages\u002FREGN_valuation_model-2-1_9566784e2f\u002FREGN_valuation_model-2-1_9566784e2f.webp?_i=AA 1024w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_244,c_scale\u002Ff_webp,q_auto\u002Fv1772593810\u002Fimages\u002FREGN_valuation_model-2-1_9566784e2f\u002FREGN_valuation_model-2-1_9566784e2f.webp?_i=AA 300w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_768,h_624,c_scale\u002Ff_webp,q_auto\u002Fv1772593810\u002Fimages\u002FREGN_valuation_model-2-1_9566784e2f\u002FREGN_valuation_model-2-1_9566784e2f.webp?_i=AA 768w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1536,h_1248,c_scale\u002Ff_webp,q_auto\u002Fv1772593810\u002Fimages\u002FREGN_valuation_model-2-1_9566784e2f\u002FREGN_valuation_model-2-1_9566784e2f.webp?_i=AA 1536w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_2048,h_1663,c_scale\u002Ff_webp,q_auto\u002Fv1772593810\u002Fimages\u002FREGN_valuation_model-2-1_9566784e2f\u002FREGN_valuation_model-2-1_9566784e2f.webp?_i=AA 2048w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1200,h_975,c_scale\u002Ff_webp,q_auto\u002Fv1772593810\u002Fimages\u002FREGN_valuation_model-2-1_9566784e2f\u002FREGN_valuation_model-2-1_9566784e2f.webp?_i=AA 1200w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1400,h_1137,c_scale\u002Ff_webp,q_auto\u002Fv1772593810\u002Fimages\u002FREGN_valuation_model-2-1_9566784e2f\u002FREGN_valuation_model-2-1_9566784e2f.webp?_i=AA 1400w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">Résultats du modèle d'évaluation de l'action REGN \u003Cstrong>(\u003C\u002Fstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?cid=21127&tid=2621295&ref=tikrblog\">\u003Cstrong>TIKR\u003C\u002Fstrong>\u003C\u002Fa>\u003Cstrong>)\u003C\u002Fstrong>\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp>Le modèle d'évaluation TIKR vise 1 226,8 $ d'ici le 31 décembre 2030, ce qui implique un rendement total de 60,0 % et un TRI annuel de 10,2 % par rapport à une action se négociant à 766,7 $ aujourd'hui.\u003C\u002Fp>\n\n\n\n\u003Cp>Le marché considère REGN comme une société pharmaceutique en voie de maturation, alors que son pipeline comporte quatre approbations de la FDA prévues pour 2026, dans trois modalités distinctes simultanément.\u003C\u002Fp>\n\n\n\n\u003Cp>Les marges de revenu net normalisées se sont maintenues à 34,1 % en 2025 malgré une baisse des bénéfices de 8,1 %, ce qui démontre une rentabilité structurelle que le multiple actuel ne récompense pas de manière adéquate.\u003C\u002Fp>\n\n\n\n\u003Cp>L'engagement de la direction de consacrer entre 5,9 et 6,1 milliards de dollars à la R&D en 2026, associé à 18 nouvelles initiations de phase 3, indique que les dirigeants considèrent que le pipeline mérite d'être financé de manière agressive, et non pas que l'entreprise est en mode de récolte.\u003C\u002Fp>\n\n\n\n\u003Cp>Les multiples lancements de biosimilaires d'EYLEA 2mg attendus au second semestre 2026 pourraient accélérer l'érosion des revenus dans la franchise rétinienne, ce qui pèserait directement sur les prévisions de marge brute de 83% à 84%.\u003C\u002Fp>\n\n\n\n\u003Cp>Les résultats de l'étude pivot fianlimab dans le mélanome métastatique de première ligne, attendus au premier semestre 2026, détermineront si Regeneron peut créer un deuxième produit phare en oncologie aux côtés de LIBTAYO.\u003C\u002Fp>\n\n\n\n\u003Cp>REGN se négocie avec une forte décote par rapport à sa juste valeur implicite de 1 226,8 $, et le résultat du fianlimab est le catalyseur qui pourrait forcer une réévaluation.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>\u003Cem>Les meilleures idées de Wall Street ne restent pas cachées longtemps. Avec TIKR, vous pouvez suivre gratuitement les mises à jour des analystes, les résultats supérieurs aux attentes et les surprises en matière de revenus pour des milliers d'actions →\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-should-you-invest-in-regeneron-pharmaceuticals-inc\">\u003Cstrong>Devriez-vous investir dans Regeneron Pharmaceuticals, Inc.\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp>La seule façon de le savoir est de consulter les chiffres vous-même. TIKR vous donne un accès gratuit aux mêmes données financières de qualité institutionnelle que celles utilisées par les analystes professionnels pour répondre à cette question.\u003C\u002Fp>\n\n\n\n\u003Cp>Sélectionnez l'action REGN et vous verrez des années de données financières historiques, les prévisions des analystes de Wall Street en matière de revenus et de bénéfices pour les trimestres à venir, l'évolution des multiples d'évaluation au fil du temps et la tendance à la hausse ou à la baisse des objectifs de prix.\u003C\u002Fp>\n\n\n\n\u003Cp>Vous pouvez créer une liste de surveillance gratuite pour suivre Regeneron Pharmaceuticals, Inc. en même temps que toutes les autres actions qui vous intéressent. Aucune carte de crédit n'est requise. Juste les données dont vous avez besoin pour décider par vous-même.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>\u003Cem>Accédez gratuitement à des outils professionnels pour analyser l'action REGN sur TIKR →\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n",792,"fr","\u002Fblog\u002Fheres-why-regeneron-stock-could-deliver-60-upside-returns","heres-why-regeneron-stock-could-deliver-60-upside-returns","images\u002FFEATURED-IMAGE-MAKER-395\u002FFEATURED-IMAGE-MAKER-395","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_360,c_scale\u002Ff_webp,q_auto\u002Fv1772594266\u002Fimages\u002FFEATURED-IMAGE-MAKER-395\u002FFEATURED-IMAGE-MAKER-395.png?_i=AA",{"altText":237,"imageCredit":238},"Here’s Why Regeneron Stock Could Deliver 60% Upside Returns","TIKR",{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":244},"Gian Estrada","giantikr","author","",[],{"name":246,"slug":247,"role":248,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":249},"Thomas Richmond","thomastikr","editor",[],[251],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},"Examens des Actions","reviews","\u002Fblog\u002Fcategory\u002Freviews",0,[],{"title":237,"metaDesc":258,"opengraphDescription":258,"twitterTitle":237,"twitterDescription":258},"Dupixent just crossed $17.8 billion in annual sales across 1.4 million patients, and with a ninth FDA approval now confirmed, analysts see 13.6% more upside before REGN even touches its mean price target.",{"title":260,"description":258,"twitterTitle":260,"twitterDescription":258,"author":240,"articlePublisher":261,"articlePublishedTime":226,"articleModifiedTime":227,"twitterLabel1":262,"twitterData1":263,"ogTitle":260,"ogDescription":258,"ogUrl":232,"ogImage":235,"ogImageWidth":264,"ogImageHeight":265,"ogImageSecureUrl":235,"ogImageAlt":237,"twitterImage":235},"Here’s Why Regeneron Stock Could Deliver 60% Upside Returns","TIKR.com","Temps de lecture estimé","6 minutes",1200,630,[267,284,299,314,329],{"id":255,"title":268,"date":269,"excerpt":270,"wordCount":271,"uri":272,"slug":273,"cloudinaryAssetId":274,"featuredImageOriginalUrl":275,"featuredImageMetadata":276,"author":277,"categories":281,"relatedPosts":283},"Duke Energy est en hausse de 12 % en 2026. Voici à quel point l'action pourrait augmenter cette année","2026-03-04 01:35:00","Duke Energy est en hausse d'environ 12 % depuis le début de l'année en 2026, et notre analyse suggère que le titre pourrait encore progresser régulièrement cette année. Voici pourquoi l'accélération de la demande en centres de données et la croissance du capital réglementé continuent de soutenir la configuration.",693,"\u002Fblog\u002Fduke-energy-is-up-12-in-2026-heres-how-much-the-stock-could-rise-this-year","duke-energy-is-up-12-in-2026-heres-how-much-the-stock-could-rise-this-year","images\u002F@Totojang-from-Getty-Images-Pro-via-Canva-12\u002F@Totojang-from-Getty-Images-Pro-via-Canva-12","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772579708\u002Fimages\u002F@Totojang-from-Getty-Images-Pro-via-Canva-12\u002F@Totojang-from-Getty-Images-Pro-via-Canva-12.png?_i=AA",{"altText":268},{"name":278,"slug":279,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":280},"Nikko Henson","nikkotikr",[],[282],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":285,"date":286,"excerpt":287,"wordCount":288,"uri":289,"slug":290,"cloudinaryAssetId":291,"featuredImageOriginalUrl":292,"featuredImageMetadata":293,"author":294,"categories":296,"relatedPosts":298},"Moody's a progressé de 3 % cette semaine. Voici à combien pourrait s'élever l'action en 2026","2026-03-04 01:05:00","Moody's a augmenté de 3 % cette semaine après avoir publié des résultats record pour 2025 et de solides prévisions pour 2026. Voici pourquoi la croissance des émissions, la dynamique du crédit privé et l'expansion des analyses à marge élevée continuent de soutenir la hausse des bénéfices cette année.",713,"\u002Fblog\u002Fmoodys-rose-3-this-week-heres-how-much-the-stock-could-rise-in-2026","moodys-rose-3-this-week-heres-how-much-the-stock-could-rise-in-2026","images\u002F@Изображения-пользователя-Axel-Makhalov-via-Canva-123\u002F@Изображения-пользователя-Axel-Makhalov-via-Canva-123","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772576067\u002Fimages\u002F@Изображения-пользователя-Axel-Makhalov-via-Canva-123\u002F@Изображения-пользователя-Axel-Makhalov-via-Canva-123.png?_i=AA",{"altText":285},{"name":278,"slug":279,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":295},[],[297],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":300,"date":301,"excerpt":302,"wordCount":303,"uri":304,"slug":305,"cloudinaryAssetId":306,"featuredImageOriginalUrl":307,"featuredImageMetadata":308,"author":309,"categories":311,"relatedPosts":313},"L'action NXP a chuté de 5 % cette semaine. Voici l'histoire de la reprise jusqu'en 2026","2026-03-04 00:35:00","NXP a chuté d'environ 5 % la semaine dernière, les investisseurs ayant réagi à la prudence des prévisions à court terme pour le secteur automobile, malgré des résultats solides. Notre analyse de la valorisation suggère que l'action pourrait encore offrir une hausse significative en 2026. Voici pourquoi la croissance du contenu par véhicule et l'expansion des marges peuvent soutenir l'histoire de la reprise.",697,"\u002Fblog\u002Fnxp-stock-dropped-5-this-week-heres-the-recovery-story-into-2026","nxp-stock-dropped-5-this-week-heres-the-recovery-story-into-2026","images\u002F@Corina-Ciocirlans-Images-via-Canva-213\u002F@Corina-Ciocirlans-Images-via-Canva-213","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772574553\u002Fimages\u002F@Corina-Ciocirlans-Images-via-Canva-213\u002F@Corina-Ciocirlans-Images-via-Canva-213.png?_i=AA",{"altText":300},{"name":278,"slug":279,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":310},[],[312],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":315,"date":316,"excerpt":317,"wordCount":318,"uri":319,"slug":320,"cloudinaryAssetId":321,"featuredImageOriginalUrl":322,"featuredImageMetadata":323,"author":324,"categories":326,"relatedPosts":328},"Atlassian a progressé de 10 % cette semaine. Voici à quelle hauteur l'action pourrait grimper en 2026","2026-03-04 00:05:00","L'action Atlassian a progressé d'environ 10 % cette semaine, et notre analyse suggère que le titre pourrait encore offrir une hausse significative en 2026. Voici pourquoi l'accélération du cloud, la monétisation de l'IA et l'expansion des entreprises d'Atlassian continuent de soutenir la configuration.",777,"\u002Fblog\u002Fatlassian-rose-10-this-week-heres-how-high-the-stock-could-climb-in-2026","atlassian-rose-10-this-week-heres-how-high-the-stock-could-climb-in-2026","images\u002F@Olivia-Grigoritas-Images-via-Canva\u002F@Olivia-Grigoritas-Images-via-Canva","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772573206\u002Fimages\u002F@Olivia-Grigoritas-Images-via-Canva\u002F@Olivia-Grigoritas-Images-via-Canva.png?_i=AA",{"altText":315},{"name":278,"slug":279,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":325},[],[327],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":330,"date":331,"excerpt":332,"wordCount":333,"uri":334,"slug":335,"cloudinaryAssetId":336,"featuredImageOriginalUrl":337,"featuredImageMetadata":338,"author":339,"categories":341,"relatedPosts":343},"GE Aerospace a augmenté de 8% au cours du dernier mois. Voici à quel point l'action pourrait grimper en 2026","2026-03-03 23:35:00","L'action GE Aerospace a augmenté de 8 % au cours du mois dernier après avoir publié des résultats solides pour le quatrième trimestre et des prévisions optimistes pour 2026. Voici pourquoi le carnet de commandes de 190 milliards de dollars de l'entreprise et la croissance attendue des services, de l'ordre de 10 %, pourraient continuer à soutenir la hausse jusqu'en 2026.",692,"\u002Fblog\u002Fge-aerospace-rose-8-in-the-last-month-heres-how-much-the-stock-could-climb-in-2026","ge-aerospace-rose-8-in-the-last-month-heres-how-much-the-stock-could-climb-in-2026","images\u002F@Chirila-Sofias-Images-via-Canva-2\u002F@Chirila-Sofias-Images-via-Canva-2","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772568370\u002Fimages\u002F@Chirila-Sofias-Images-via-Canva-2\u002F@Chirila-Sofias-Images-via-Canva-2.png?_i=AA",{"altText":330},{"name":278,"slug":279,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":340},[],[342],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],[345,366,381,396,411,429,441,456,470,485],{"id":255,"title":346,"date":347,"excerpt":348,"wordCount":349,"uri":350,"slug":351,"cloudinaryAssetId":352,"featuredImageOriginalUrl":353,"featuredImageMetadata":354,"author":356,"categories":360,"relatedPosts":365},"L'action Albemarle est en tête des pertes du S&P 500, le producteur de lithium chutant de 8 %.","2026-03-04 10:58:00","Les actions d'Albemarle chutent de 8 % en raison de la chute de 13 % des prix du lithium en Chine. La faiblesse des ventes de VE de BYD et les tensions au Moyen-Orient assombrissent les perspectives de la demande pour le producteur.",596,"\u002Fblog\u002Falbemarle-nyse-stock-leads-sp-500-losses-as-lithium-producer-sinks-8","albemarle-nyse-stock-leads-sp-500-losses-as-lithium-producer-sinks-8","images\u002FALB-stock\u002FALB-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772620530\u002Fimages\u002FALB-stock\u002FALB-stock.png?_i=AA",{"altText":355},"L'action Albemarle est en tête des pertes du S&P 500, le producteur de lithium chutant de 8 %.",{"name":357,"slug":358,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":359},"Aditya Raghunath","adityatikr",[],[361],{"name":362,"slug":363,"uri":364,"description":243,"postsCount":255},"Investissement Général","general-investing","\u002Fblog\u002Fcategory\u002Fgeneral-investing",[],{"id":255,"title":367,"date":368,"excerpt":369,"wordCount":370,"uri":371,"slug":372,"cloudinaryAssetId":373,"featuredImageOriginalUrl":374,"featuredImageMetadata":375,"author":376,"categories":378,"relatedPosts":380},"Barclays ramène la note de l'action Blue Owl à \"Equal Weight\" alors que la chute du cours de l'action se poursuit","2026-03-03 11:59:00","Barclays abaisse la note de Blue Owl Capital en raison d'un fort ralentissement des entrées de capitaux dans les BDC non cotées et d'une forte augmentation des rachats. L'action a baissé de 50 % au cours de l'année écoulée en raison des craintes liées au crédit.",775,"\u002Fblog\u002Fbarclays-cuts-blue-owl-nyse-owl-stock-rating-equal-weight-price-plunge","barclays-cuts-blue-owl-nyse-owl-stock-rating-equal-weight-price-plunge","images\u002FOWL-stock-1\u002FOWL-stock-1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772533744\u002Fimages\u002FOWL-stock-1\u002FOWL-stock-1.png?_i=AA",{"altText":367},{"name":357,"slug":358,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":377},[],[379],{"name":362,"slug":363,"uri":364,"description":243,"postsCount":255},[],{"id":255,"title":382,"date":383,"excerpt":384,"wordCount":385,"uri":386,"slug":387,"cloudinaryAssetId":388,"featuredImageOriginalUrl":389,"featuredImageMetadata":390,"author":391,"categories":393,"relatedPosts":395},"L'action Novo Nordisk atteint son plus bas niveau en 52 semaines, Goldman Sachs la rétrograde à \"neutre\".","2026-03-03 10:55:00","L'action Block a augmenté de plus de 20 % après que la société fintech a annoncé qu'elle allait licencier plus de 4 000 employés, soit environ la moitié de ses effectifs.",655,"\u002Fblog\u002Fnovo-nordisk-nyse-nvo-stock-hits-52-week-low-as-goldman-sachs-downgrades-it-to-neutral","novo-nordisk-nyse-nvo-stock-hits-52-week-low-as-goldman-sachs-downgrades-it-to-neutral","images\u002FNVO-stock_954941bea1\u002FNVO-stock_954941bea1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772532602\u002Fimages\u002FNVO-stock_954941bea1\u002FNVO-stock_954941bea1.png?_i=AA",{"altText":382},{"name":357,"slug":358,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":392},[],[394],{"name":362,"slug":363,"uri":364,"description":243,"postsCount":255},[],{"id":255,"title":397,"date":398,"excerpt":399,"wordCount":400,"uri":401,"slug":402,"cloudinaryAssetId":403,"featuredImageOriginalUrl":404,"featuredImageMetadata":405,"author":406,"categories":408,"relatedPosts":410},"Le financement massif d'OpenAI déclenche la chute des actions d'Amazon","2026-03-02 10:30:00","L'action d'Amazon a chuté après la levée de fonds de 110 milliards de dollars d'OpenAI, malgré l'engagement d'Amazon à hauteur de 50 milliards de dollars et la conclusion d'un accord de partenariat majeur avec AWS.",831,"\u002Fblog\u002Fopenai-massive-funding-round-triggers-selloff-in-amazon-nasdaq-amzn-stock","openai-massive-funding-round-triggers-selloff-in-amazon-nasdaq-amzn-stock","images\u002FAMZN-stock-1\u002FAMZN-stock-1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772278707\u002Fimages\u002FAMZN-stock-1\u002FAMZN-stock-1.png?_i=AA",{"altText":397},{"name":357,"slug":358,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":407},[],[409],{"name":362,"slug":363,"uri":364,"description":243,"postsCount":255},[],{"id":255,"title":412,"date":413,"excerpt":414,"wordCount":415,"uri":416,"slug":417,"cloudinaryAssetId":418,"featuredImageOriginalUrl":419,"featuredImageMetadata":420,"author":421,"categories":423,"relatedPosts":428},"En baisse de 9 % par rapport à son plus haut niveau historique, l'action Stryker peut-elle offrir de nouveaux rendements en 2026 ?","2026-03-04 10:55:00","La forte dynamique du Mako et la croissance robuste du MedSurg sont à l'origine des perspectives de Stryker. L'action pourrait atteindre 503 $ d'ici 2028, ce qui représente une hausse de 30 % par rapport aux niveaux actuels.",1262,"\u002Fblog\u002Fdown-9-from-all-time-high-can-stryker-nyse-stock-deliver-further-returns-in-2026","down-9-from-all-time-high-can-stryker-nyse-stock-deliver-further-returns-in-2026","images\u002FSYK-stock\u002FSYK-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772517855\u002Fimages\u002FSYK-stock\u002FSYK-stock.png?_i=AA",{"altText":412},{"name":357,"slug":358,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":422},[],[424],{"name":425,"slug":426,"uri":427,"description":243,"postsCount":255},"Évaluation","valuation","\u002Fblog\u002Fcategory\u002Fvaluation",[],{"id":255,"title":430,"date":413,"excerpt":431,"wordCount":415,"uri":432,"slug":433,"cloudinaryAssetId":-1,"featuredImageOriginalUrl":434,"featuredImageMetadata":435,"author":436,"categories":438,"relatedPosts":440},"En hausse de 54 % au cours des 12 derniers mois, l'action Analog Devices peut-elle continuer sur sa lancée en 2026 ?","L'action d'Analog Devices a bondi de 56 % en 12 mois grâce à la demande d'infrastructures d'IA. Cette dynamique peut-elle se poursuivre ? Nous analysons l'objectif de cours de 422 $ d'ADI et son potentiel de hausse de 20 %.","\u002Fblog\u002Fup-56-in-last-12-months-can-analog-devices-nyse-adi-stock-continue-its-strong-run-in-2026","up-56-in-last-12-months-can-analog-devices-nyse-adi-stock-continue-its-strong-run-in-2026","https:\u002F\u002Ftikr1.wpengine.com\u002Fwp-content\u002Fuploads\u002F2026\u002F03\u002FADI-stock-600x400.png",{"altText":430},{"name":357,"slug":358,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":437},[],[439],{"name":425,"slug":426,"uri":427,"description":243,"postsCount":255},[],{"id":255,"title":442,"date":443,"excerpt":444,"wordCount":445,"uri":446,"slug":447,"cloudinaryAssetId":448,"featuredImageOriginalUrl":449,"featuredImageMetadata":450,"author":451,"categories":453,"relatedPosts":455},"En baisse de 25 % par rapport à son plus haut niveau historique, l'action Capital One peut-elle offrir de meilleurs rendements en 2026 ?","2026-03-03 11:25:00","L'action Capital One pourrait générer des rendements de 30 % d'ici 2028, l'intégration de Discover et l'acquisition de Brex débloquant la croissance du réseau de paiements et l'expansion des services bancaires aux entreprises.",1309,"\u002Fblog\u002Fdown-25-from-all-time-high-can-capital-one-nyse-stock-deliver-better-returns-in-2026","down-25-from-all-time-high-can-capital-one-nyse-stock-deliver-better-returns-in-2026","images\u002FCOF-stock\u002FCOF-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772516734\u002Fimages\u002FCOF-stock\u002FCOF-stock.png?_i=AA",{"altText":442},{"name":357,"slug":358,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":452},[],[454],{"name":425,"slug":426,"uri":427,"description":243,"postsCount":255},[],{"id":255,"title":457,"date":383,"excerpt":458,"wordCount":459,"uri":460,"slug":461,"cloudinaryAssetId":462,"featuredImageOriginalUrl":463,"featuredImageMetadata":464,"author":465,"categories":467,"relatedPosts":469},"En hausse de 20 % au cours des 12 derniers mois, l'action Synchrony Financial peut-elle évoluer à la hausse en 2026 ?","En hausse de 20% sur 12 mois, Synchrony Financial est prometteur avec la croissance du partenariat avec Walmart. Notre modèle prévoit une hausse de 27 % à 87 $ d'ici décembre 2028. Analyse à l'intérieur.",1261,"\u002Fblog\u002Fup-20-in-last-12-months-can-synchrony-financial-syf-stock-deliver-further-in-2026","up-20-in-last-12-months-can-synchrony-financial-syf-stock-deliver-further-in-2026","images\u002FSYF-stock\u002FSYF-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772512295\u002Fimages\u002FSYF-stock\u002FSYF-stock.png?_i=AA",{"altText":457},{"name":357,"slug":358,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":466},[],[468],{"name":425,"slug":426,"uri":427,"description":243,"postsCount":255},[],{"id":255,"title":471,"date":472,"excerpt":473,"wordCount":474,"uri":475,"slug":476,"cloudinaryAssetId":477,"featuredImageOriginalUrl":478,"featuredImageMetadata":479,"author":480,"categories":482,"relatedPosts":484},"En hausse de 42 % en 3 ans, l'action de Raymond James Financial peut-elle continuer à progresser ?","2026-03-03 09:55:00","L'action Raymond James a baissé de 10 % en 12 mois. Un fort recrutement, 31 milliards de dollars de nouveaux actifs nets signalent une reprise. Notre modèle prévoit une hausse de 21 % pour atteindre 185 $ d'ici septembre 2028.",1234,"\u002Fblog\u002Fup-42-in-3-years-can-raymond-james-financial-nyse-rjf-stock-deliver-further","up-42-in-3-years-can-raymond-james-financial-nyse-rjf-stock-deliver-further","images\u002FRJF-stock_9542509878\u002FRJF-stock_9542509878","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772467602\u002Fimages\u002FRJF-stock_9542509878\u002FRJF-stock_9542509878.png?_i=AA",{"altText":471},{"name":357,"slug":358,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":481},[],[483],{"name":425,"slug":426,"uri":427,"description":243,"postsCount":255},[],{"id":255,"title":486,"date":413,"excerpt":487,"wordCount":488,"uri":489,"slug":490,"cloudinaryAssetId":491,"featuredImageOriginalUrl":492,"featuredImageMetadata":493,"author":494,"categories":496,"relatedPosts":501},"Pourquoi l'action d'AeroVironment a chuté de plus de 20 % cette semaine","AeroVironment plonge de 19 % après que l'armée de l'espace a rouvert l'appel d'offres pour un contrat SCAR de 1,4 milliard de dollars. Raymond James rétrograde l'action de \"strong buy\" à \"underperform\".",799,"\u002Fblog\u002Fwhy-aerovironment-avav-stock-tanked-over-20-this-week","why-aerovironment-avav-stock-tanked-over-20-this-week","images\u002FAVAV-stock_955099f985\u002FAVAV-stock_955099f985","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772536085\u002Fimages\u002FAVAV-stock_955099f985\u002FAVAV-stock_955099f985.png?_i=AA",{"altText":486},{"name":357,"slug":358,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":495},[],[497],{"name":498,"slug":499,"uri":500,"description":243,"postsCount":255},"Mises à Jour des Résultats","earnings-updates","\u002Fblog\u002Fcategory\u002Fearnings-updates",[]]